CD73 expression and clinical significance in human metastatic melanoma.

Détails

Ressource 1Télécharger: PMID29928476.pdf (3808.86 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_11E2460193C6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
CD73 expression and clinical significance in human metastatic melanoma.
Périodique
Oncotarget
Auteur⸱e⸱s
Monteiro I., Vigano S., Faouzi M., Treilleux I., Michielin O., Ménétrier-Caux C., Caux C., Romero P., de Leval L.
ISSN
1949-2553 (Electronic)
ISSN-L
1949-2553
Statut éditorial
Publié
Date de publication
01/06/2018
Peer-reviewed
Oui
Volume
9
Numéro
42
Pages
26659-26669
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
CD73 is an ectoenzyme involved in the production of adenosine. It exerts immunosuppressive and protumoral roles and has emerged as a potential immuno-oncology target.
CD73 expression was detected in TC in 54% of melanoma metastases, involving < 50% TC in the majority of the cases, with variable intensity. CD73 expression was significantly associated with a lower Breslow's depth of the primary lesion and was more frequent in patients having received prior non-surgical therapies. In an adjusted analysis, CD73 expression in TC (H-score > 37.5 or intensity > 1) significantly correlated to decreased overall survival (OS) from biopsy. Of the samples containing TIMC, 35% presented CD73+ TIMC. Highly infiltrated tumors were more likely to contain CD73+ TIMC. CD73 expression in TIMC (percentage ≥1%) significantly correlated with improved OS from biopsy.
Immunohistochemistry detected CD73 expression in more than half of metastatic melanomas. While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS. These results encourage the study of anti-CD73 therapies for metastatic melanoma patients.
CD73 expression was assessed by immunohistochemistry in metastatic melanomas from 114 patients. Immunostainings were evaluated in tumor cells (TC) (percentage, intensity (1-3) and H-score) and in tumor-infiltrating mononuclear cells (TIMC) (percentage).
Mots-clé
CD73, ecto-5'-nucleotidase, immunohistochemistry, melanoma, prognosis
Pubmed
Open Access
Oui
Création de la notice
26/06/2018 9:10
Dernière modification de la notice
21/11/2022 9:29
Données d'usage